Copy For Citation
Bengoa S. Y., Ataseven E., Kizmazoglu D., Yenigurbuz F. D., Erdem M., ÖREN H.
Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.34, no.1, pp.46-51, 2017 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
34
Issue:
1
-
Publication Date:
2017
-
Doi Number:
10.4274/tjh.2015.0411
-
Journal Name:
Turkish journal of haematology : official journal of Turkish Society of Haematology
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
-
Page Numbers:
pp.46-51
-
Keywords:
Relapsed/refractory leukemia, FLAG regimen, Chemotherapy, Childhood, ACUTE MYELOGENOUS LEUKEMIA, COLONY-STIMULATING FACTOR, ACUTE MYELOID-LEUKEMIA, RELAPSED ACUTE-LEUKEMIA, HIGH-DOSE CYTARABINE, G-CSF, RANDOMIZED-TRIAL, FLUDARABINE, CHILDHOOD, THERAPY
-
Dokuz Eylül University Affiliated:
Yes
Abstract
Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia.